TABLE 2.
Basic characteristics of the four included human studies.
| Study ID | Country | Male/female | Number of experimental group | Number of control group | Treatment group (method to curcumin) | Control group | Duration | Time of following-up | Outcomes | p-Value |
|---|---|---|---|---|---|---|---|---|---|---|
| Arintaya Phrommintikul. 2019 | Thailand | 69/31 | 50 | 50 | Curcumin treatment: curcumin nanomicelle 4 g per day P.O for 1 day before PCI and 1day post PCI Conventional treatment: Not mention | Conventional treatment: Not mention | 2 days | 48 h after PCI | 1.hs-TnT after PCI | 1.p = 0.912 |
| 2.hs-CRP after PCI | 2.p = 0.873 | |||||||||
| Naser Aslanabadi. 2019 | Iran | 66/44 | 55 | 55 | Curcumin treatment: curcumin nanomicelle 480 mg P.O at 1–2 h before PCI Conventional treatment: aspirin 325 mg and clopidogrel 300 mg orally plus weight-adjusted intravenous heparin with a target activated clotting time 250–350 s | Pretreatment: aspirin 325 mg and clopidogrel 300 mg orally plus weight-adjusted intravenous heparin with a target activated clotting time 250–350 s | once | 8 and 24 h after PCI | 1.CK-MB 8 h after PCI | 1.p = 0.24 |
| 2.CK-MB 24 h after PCI | 2.p = 0.37 | |||||||||
| 3.cTnI 8 h after PCI | 3.p = 1.0 | |||||||||
| 4.cTnI 24 h after PCI | 4.p = 0.35 | |||||||||
| Wanwarang Wongcharoen. 2012 | Thailand | 69/52 | 61 | 60 | Curcumin treatment: curcumin nanomicelle 4 g per day P.O for 3 days before CABG and 5 days post CABG Conventional treatment: Not mention | Conventional treatment: Not mention | 8 days | 30 days after CABG | 1.CRP 3 days after CABG | 1.p = 0.031 |
| 2.CRP 5 days after CABG | 2.p > 0.05 | |||||||||
| 3.MDA 5 days after CABG | 3.p < 0.001 | |||||||||
| 4. Incidence of in-hospital MI | 4.p = 0.028 | |||||||||
| 5. Incidence of left ventricular dysfunction | 5.p = 0.021 | |||||||||
| 6.NT-proBNP | 6.0.015 | |||||||||
| W. Wongcharoen. 2011 | Thailand | Not mention | 52 | 52 | Curcumin treatment: curcumin nanomicelle 4 g per day P.O for 3 days before CABG and 7 days post CABG Conventional treatment: Not mention | Conventional treatment: Not mention | 10 days | 30 days after CABG | 1. Incidence of in-hospital MI | 1.p < 0.05 |
| 2. Incidence of MACE | 2.p < 0.05 | |||||||||
| 3.CK-MB after CABG | 3.p < 0.05 |
CABG, coronary artery bypass grafting; CK-MB, creatine kinase; MB, form; cTnI, cardiac troponin; hs-CRP, high-sensitive cardiac troponin T; hs-TnT, high-sensitive cardiac troponin T; MACE, major adverse cardiovascular events; MDA, malonaldehyde; MI, myocardium infarction; P.O, peros; PCI, percutaneous coronary intervention.